Dr. Reddy Laboratories (RDY)

Add to Watchlists Create an Alert
37.54 +0.22  +0.59%   NYSE May 24, 5:00PM BATS Real time Currency in USD

Dr. Reddy Laboratories SG&A Expense Quarterly:

156.00M for Dec. 31, 2012
View Full Chart

Dr. Reddy Laboratories SG&A Expense Quarterly Chart

    Dr. Reddy Laboratories Historical SG&A Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 156.00M
    Sept. 30, 2012 151.17M
    June 30, 2012 145.73M
    March 31, 2012 131.58M
    Dec. 31, 2011 144.89M
    Sept. 30, 2011 148.04M
    June 30, 2011 150.31M
    March 31, 2011 137.19M
    Dec. 31, 2010 141.90M
    Sept. 30, 2010 126.70M
    June 30, 2010 118.10M
    March 31, 2010 129.33M
    Dec. 31, 2009 116.80M
    Sept. 30, 2009 111.03M
    June 30, 2009 123.40M
    March 31, 2009 103.32M
    Dec. 31, 2008 111.08M
    Sept. 30, 2008 113.69M
    June 30, 2008 119.05M
       
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro

    About SG&A Expense

    SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

    The details of how SG&A expenses are calculated vary widely from company to company, so YCharts recommends looking at the annual report (10-k) an investor is interested in dissecting this number further.
    Learn More

    Get data for

    RDY SG&A Expense Quarterly Benchmarks

    Companies
    Mylan 351.37M
    Akorn 12.34M
    Valeant Pharmaceuticals International 246.35M

    RDY SG&A Expense Quarterly Rankings

    Overall 90th percentile
    772 of 8009
    Sector 88th percentile
    77 of 687 in Healthcare
    Industry 85th percentile
    10 of 69 in Drug Manufacturers - Specialty & Generic

    RDY SG&A Expense Quarterly Range, Past 5 Years

    Minimum 103.32M Mar 2009
    Maximum 156.00M Dec 2012
    Average 130.49M